# MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)

> **NCT03412292** · PHASE1 · UNKNOWN · sponsor: **Maxinovel Pty., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Acute Myelogenous Leukemia (AML)

## Interventions

- **DRUG:** MAX-40279

## Key facts

- **NCT ID:** NCT03412292
- **Lead sponsor:** Maxinovel Pty., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-01
- **Primary completion:** 2022-11-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03412292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03412292, "MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03412292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*